author-photo

Pooja Bhagia

Merck & Co.

33

Papers

483

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (10)
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score {greater than or equal to}10.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (12)
Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (9)
P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.

2021 Gastric Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.

2021 Esophagus
Show All
- Source
- Cite
- Save
Citations (0)
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)